Goldman Sachs employees named as suspects in Brazil fraud probe

Two Goldman Sachs employees have been formally indicted by São Paulo civil police in connection with an alleged fraud scheme involving Oncoclinicas do Brasil Serviços Médicos, one of Brazil’s largest cancer-treatment companies. The probe centers on whether the pair helped obscure the true ownership structure of the firm to avoid triggering a costly mandatory buyout of minority shareholders.

The employees, Felipe Guerra Acosta and Natan Lima Reinig, are accused of misrepresenting ownership stakes held through a series of investment vehicles known as Josephina I, II, and later Josephina III. If the allegations hold up, the maneuver allowed major shareholders to quietly breach a critical ownership threshold without facing the consequences baked into the company’s own bylaws.

The poison pill problem

At the heart of the case is a corporate governance mechanism that many public companies use to protect minority investors. Oncoclinicas’ bylaws include a “poison pill” provision, a rule designed to prevent any single party from amassing too much control without compensating other shareholders. In this case, the trigger point was 15% ownership.

Cross that line, and the controlling party would be required to launch a mandatory public tender offer, known in Brazil as an OPA (oferta pública de aquisição). Police estimate the cost of such an offer would have been approximately R$6 billion, or roughly $1.1B at recent exchange rates.

The alleged scheme involved structuring ownership through the Josephina funds in a way that made it appear no single party had crossed the 15% mark. Public documents filed with regulators and made available to investors purportedly conveyed that an OPA was unnecessary. Minority shareholders, in other words, were left holding stakes in a company whose ownership dynamics were allegedly not what they seemed.

How it unfolded

Oncoclinicas went public in 2021, a period when Brazilian healthcare companies attracted significant investor interest. Following the IPO, the company made disclosures that attributed indirect ownership of the Josephina funds solely to Goldman Sachs, omitting any mention of U.S. fund manager Centaurus. Tensions escalated in November 2024 when Centaurus was claimed to already possess indirect ownership, raising concerns among minority shareholders that the subsequent restructuring of the funds was designed to evade the poison pill provision. The police have maintained that this late explanation contradicts previous market disclosures.

São Paulo’s civil police eventually caught wind of the arrangement and opened a formal investigation. The August 10, 2026 indictment marks the most significant escalation yet, putting named Goldman Sachs personnel directly in the crosshairs of Brazilian law enforcement.

What this means for Goldman and emerging market investing

For minority shareholders in Oncoclinicas specifically, the stakes are significant. If courts ultimately determine that the 15% threshold was indeed breached, a mandatory tender offer could still be ordered. That would force the controlling party to bid for remaining shares at a fair price, a potentially transformative event for investors who bought in at the 2021 IPO or afterward.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.